Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans

Alice Cho, Frauke Muecksch, Zijun Wang, Tarek Ben Tanfous, Justin Dasilva, Raphael Raspe, Brianna Johnson, Eva Bednarski, Victor Ramos, Dennis Schaefer-Babajew, Irina Shimeliovich, Juan P. Dizon, Kai Hui Yao, Fabian Schmidt, Katrina G. Millard, Martina Turroja, Mila Jankovic, Thiago Y. Oliveira, Anna Gazumyan, Christian GaeblerMarina Caskey, Theodora Hatziioannou, Paul D. Bieniasz, Michel C. Nussenzweig

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


The single-dose Ad.26.COV.2 (Janssen) vaccine elicits lower levels of neutralizing antibodies and shows more limited efficacy in protection against infection than either of the two available mRNA vaccines. In addition, Ad.26.COV.2 has been less effective in protection against severe disease during the Omicron surge. Here, we examined the memory B cell response to single-dose Ad.26.COV.2 vaccination. Compared with mRNA vaccines, Ad.26.COV.2 recipients had significantly lower numbers of RBDspecific memory B cells 1.5 or 6 mo after vaccination. Despite the lower numbers, the overall quality of the memory B cell responses appears to be similar, such that memory antibodies elicited by both vaccine types show comparable neutralizing potency against SARS-CoV-2 Wuhan-Hu-1, Delta, and Omicron BA.1 variants. The data help explain why boosting Ad.26.COV.2 vaccine recipients with mRNA vaccines is effective and why the Ad26.COV2.S vaccine can maintain some protective efficacy against severe disease during the Omicron surge.
Original languageEnglish (US)
JournalJournal of Experimental Medicine
Issue number8
StatePublished - Aug 1 2022
Externally publishedYes

Bibliographical note

Generated from Scopus record by KAUST IRTS on 2023-02-15


Dive into the research topics of 'Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans'. Together they form a unique fingerprint.

Cite this